210 related articles for article (PubMed ID: 15054115)
1. DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties.
Valenzano KJ; Miller W; Chen Z; Shan S; Crumley G; Victory SF; Davies E; Huang JC; Allie N; Nolan SJ; Rotshteyn Y; Kyle DJ; Broglé K
J Pharmacol Exp Ther; 2004 Aug; 310(2):783-92. PubMed ID: 15054115
[TBL] [Abstract][Full Text] [Related]
2. DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity: II. In vivo pharmacological characterization in the rat.
Whiteside GT; Harrison JE; Pearson MS; Chen Z; Fundytus ME; Rotshteyn Y; Turchin PI; Pomonis JD; Mark L; Walker K; Broglé KC
J Pharmacol Exp Ther; 2004 Aug; 310(2):793-9. PubMed ID: 15054116
[TBL] [Abstract][Full Text] [Related]
3. The role of central and peripheral mu opioid receptors in inflammatory pain and edema: a study using morphine and DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid).
Whiteside GT; Boulet JM; Walker K
J Pharmacol Exp Ther; 2005 Sep; 314(3):1234-40. PubMed ID: 15937151
[TBL] [Abstract][Full Text] [Related]
4. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
5. Contribution of opioid receptors on primary afferent versus sympathetic neurons to peripheral opioid analgesia.
Zhou L; Zhang Q; Stein C; Schäfer M
J Pharmacol Exp Ther; 1998 Aug; 286(2):1000-6. PubMed ID: 9694961
[TBL] [Abstract][Full Text] [Related]
6. Peripherally mediated antinociception of the mu-opioid receptor agonist 2-[(4,5alpha-epoxy-3-hydroxy-14beta-methoxy-17-methylmorphinan-6beta-yl)amino]acetic acid (HS-731) after subcutaneous and oral administration in rats with carrageenan-induced hindpaw inflammation.
Bileviciute-Ljungar I; Spetea M; Guo Y; Schütz J; Windisch P; Schmidhammer H
J Pharmacol Exp Ther; 2006 Apr; 317(1):220-7. PubMed ID: 16339394
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
[TBL] [Abstract][Full Text] [Related]
8. Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity.
DeHaven-Hudkins DL; Burgos LC; Cassel JA; Daubert JD; DeHaven RN; Mansson E; Nagasaka H; Yu G; Yaksh T
J Pharmacol Exp Ther; 1999 Apr; 289(1):494-502. PubMed ID: 10087042
[TBL] [Abstract][Full Text] [Related]
9. The roles of different subtypes of opioid receptors in mediating the nucleus submedius opioid-evoked antiallodynia in a neuropathic pain model of rats.
Wang JY; Zhao M; Yuan YK; Fan GX; Jia H; Tang JS
Neuroscience; 2006; 138(4):1319-27. PubMed ID: 16472929
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958.
Hawkinson JE; Szoke BG; Garofalo AW; Hom DS; Zhang H; Dreyer M; Fukuda JY; Chen L; Samant B; Simmonds S; Zeitz KP; Wadsworth A; Liao A; Chavez RA; Zmolek W; Ruslim L; Bova MP; Holcomb R; Butelman ER; Ko MC; Malmberg AB
J Pharmacol Exp Ther; 2007 Aug; 322(2):619-30. PubMed ID: 17470643
[TBL] [Abstract][Full Text] [Related]
11. Opioid peptide receptor studies. 7. The methylfentanyl congener RTI-4614-4 and its four enantiomers bind to different domains of the rat mu opioid receptor.
Lu YF; Xu H; Liu-Chen LY; Chen C; Partilla JS; Brine GA; Carroll FI; Rice KC; Lai J; Porreca F; Sadee W; Rothman RB
Synapse; 1998 Feb; 28(2):117-24. PubMed ID: 9450512
[TBL] [Abstract][Full Text] [Related]
12. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
[TBL] [Abstract][Full Text] [Related]
13. Roles of different subtypes of opioid receptors in mediating the ventrolateral orbital cortex opioid-induced inhibition of mirror-neuropathic pain in the rat.
Zhao M; Wang JY; Jia H; Tang JS
Neuroscience; 2007 Feb; 144(4):1486-94. PubMed ID: 17184926
[TBL] [Abstract][Full Text] [Related]
14. FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious kappa opioid agonist with unprecedented selectivity.
Vanderah TW; Schteingart CD; Trojnar J; Junien JL; Lai J; Riviere PJ
J Pharmacol Exp Ther; 2004 Jul; 310(1):326-33. PubMed ID: 14993260
[TBL] [Abstract][Full Text] [Related]
15. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
16. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
17. The novel compound (+/-)-1-[10-((E)-3-Phenyl-allyl)-3,10-diaza-bicyclo[4.3.1]dec-3-yl]-propan-1-one (NS7051) attenuates nociceptive transmission in animal models of experimental pain; a pharmacological comparison with the combined mu-opioid receptor agonist and monoamine reuptake inhibitor tramadol.
Munro G; Baek CA; Erichsen HK; Nielsen AN; Nielsen EØ; Scheel-Kruger J; Weikop P; Peters D
Neuropharmacology; 2008 Feb; 54(2):331-43. PubMed ID: 18037451
[TBL] [Abstract][Full Text] [Related]
18. Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia.
Chen SR; Pan HL
J Neurophysiol; 2006 May; 95(5):3086-96. PubMed ID: 16467418
[TBL] [Abstract][Full Text] [Related]
19. Functional reduction in mu-opioidergic system in the spinal cord under a neuropathic pain-like state following chronic ethanol consumption in the rat.
Narita M; Miyoshi K; Narita M; Suzuki T
Neuroscience; 2007 Feb; 144(3):777-82. PubMed ID: 17156932
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites.
Dardonville C; Fernandez-Fernandez C; Gibbons SL; Ryan GJ; Jagerovic N; Gabilondo AM; Meana JJ; Callado LF
Bioorg Med Chem; 2006 Oct; 14(19):6570-80. PubMed ID: 16797997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
